Sofosbuvir is the backbone of a treatment regimen that can cure hepatitis C in just 12 weeks. In Europe, where Gilead has sought patent protection for the drug, the company charges as much as €43,000 per 12-week treatment of sofosbuvir. In the United States, Gilead initially set the price at US$84,000 per 12-week treatment – a staggering $1,000 per pill. In countries where patent barriers don’t exist, generic competition has driven the price of this drug to below $100 per 12-week treatment.
Oral drugs called direct-acting antivirals (DAAs) represent a major breakthrough in the treatment of hepatitis C, resulting in cure rates of more than 90%. DAAs are safer, more tolerable and more effective compared to older treatments for hepatitis C.
At the press briefing, speakers will share an update on the sofosbuvir patent opposition filed at European Patent Office. Speakers will also provide details about the hearing taking place on 13 and 14 September and its importance in scaling up access to treatment for people living with hepatitis C in Europe.
WHEN: Tuesday 11 September, 14:30-16:00 CEST
- Olivier Maguet, Médecins du Monde (MdM)
- Clare Groves, treated and cured of Hepatitis C under National Health System, UK
- Gaelle Krikorian, Médecins Sans Frontières (MSF) Access Campaign
HOW TO JOIN: Online via Zoom. Please register in advance for this meeting:
After registering, you will receive a confirmation email containing information about joining the meeting.
CONTACT FOR INFORMATION:
Shailly Gupta: +41 79 203 13 02 / firstname.lastname@example.org